Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Qiagen N : COVID-19 - More Testing Kits Desperately Needed - NCDC

04/27/2020 | 04:00am EST

Director-General, Nigeria Centre for Disease Control, Chikwe Ihekweazu, says Nigeria is desperately in need of more ribonucleic acid COVID-19 test kits.

In a tweet yesterday, the NCDC boss said this became important as the country expanded testing for the virus.

"We're desperately looking for more RNA extraction kits as we expand #COVID19 testing.

"Product: Total viral RNA extraction kits (preferably spin column and with a lysis buffer). Manufacturers: Qiagen, ThermoFischer, SeeGene, Inqaba, LifeRiver etc," he said.

Copyright Daily Trust. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
QIAGEN N.V. 0.02% 53.2 Delayed Quote.0.66%
SEEGENE INC End-of-day quote.
All news about QIAGEN N.V.
01/08DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..
DJ
01/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
01/08QIAGEN : Announces Appointment of New Supervisory Board Member
BU
01/07QIAGEN N : Announces Global Distribution Agreement for the COSMIC Database from ..
PU
01/06QIAGEN NV : Gets a Neutral rating from NorldLB
MD
01/06Siemens Healthineers proposes Peer Schatz to Annual Shareholders' Meeting as ..
AQ
01/05QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
2020DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..
DJ
2020DGAP-CMS : QIAGEN N.V.: Release of a capital market information
DJ
2020DGAP-DD : QIAGEN N.V. english
DJ
More news
Financials (USD)
Sales 2020 1 876 M - -
Net income 2020 294 M - -
Net Debt 2020 1 069 M - -
P/E ratio 2020 41,9x
Yield 2020 -
Capitalization 12 098 M 12 098 M -
EV / Sales 2020 7,02x
EV / Sales 2021 5,94x
Nbr of Employees 5 300
Free-Float 93,0%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | QGEN | NL0012169213 | MarketScreener
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,67 $
Last Close Price 53,20 $
Spread / Highest target 24,1%
Spread / Average Target 6,52%
Spread / Lowest Target -22,9%
EPS Revisions
Managers and Directors
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.0.66%12 098
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601